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Background and Aims: Hepatocyte growth factor (HGF) is a multifunctional pleiotropic
protein involved in tissue regeneration, protection, angiogenesis, anti-inflammatory
and anti-fibrotic responses, and tumorigenesis, through binding to its receptor MET.
Recombinant HGF protein has been shown to mitigate various liver disease models,
such as alcohol-induced liver injury, hepatic ischemia-reperfusion injury, and fibrosis. This
study aimed to investigate the anti-inflammatory, anti-fibrotic, and anti-lipogenic effects
of exogenous administration of feline HGF on a non-alcoholic steatohepatitis (NASH)
mouse model.
Methods: Wild-type C57BL/6 mice were fed a choline-deficient amino acid defined
(CDAA) diet for 3 weeks to create the mouse model of NASH, which displays hepatic
steatosis, inflammation, injury, and very mild fibrosis. One mg/kg of recombinant feline
HGF was administered intravenously daily in the last 7 days of the total 3 weeks of CDAA
diet feeding. Then, hepatic steatosis, inflammation, injury, and fibrogenic gene expression
was examined.
Results: After 3 weeks of a CDAA diet-feeding, the vehicle-treated mice
exhibited evident deposition of lipid droplets in hepatocytes, inflammatory cell
infiltration, and hepatocyte ballooning along with increased serum ALT levels whereas
recombinant HGF-treated mice showed reduced hepatic steatosis, inflammation, and
ballooned hepatocytes with a reduction of serum ALT levels. Recombinant HGF
administration promoted hepatocyte proliferation. Increased hepatic lipid accumulation
was accompanied by elevated expression of lipogenesis genes Fasn and Dgat1
in vehicle-treated mice. In HGF-treated mice, these genes were reduced with a
decrease of lipid accumulation in the liver. Consistent with the anti-inflammatory
property of HGF, augmented macrophage infiltration and upregulation of chemokines,
Cxcl1, Ccl2, and Ccl5 in the CDAA diet fed mice, were suppressed by the
addition of the HGF treatment. Finally, we examined the fibrotic response.
The vehicle-treated mice had mild fibrosis with upregulation of Col1a1, Acta2,
Yang et al. Recombinant HGF Prevents Mouse NAFLD
Timp1, Tgfb1, and Serpine1 expression. Recombinant HGF treatment significantly
suppressed fibrogenic gene expression and collagen deposition in the liver.
Conclusion: Recombinant feline HGF treatment suppressed the progression of NASH
in a CDAA diet feeding mouse model.This suggests that recombinant HGF protein has
therapeutic potential for NASH.
Keywords: HGF, NAFLD, NASH, recombinant, inflammation
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a hepatic
manifestation of metabolic syndrome, which is characterized
by excessive accumulation of fat content in hepatocytes. The
development of NAFLD is highly associated with obesity and
type 2 diabetes. Currently, 25% of adults suffer from NAFLD in
the United States. NAFLD encompasses two clinicopathological
entities, simple steatosis and non-alcoholic steatohepatitis
(NASH). NASH is histologically characterized by hepatic
steatosis along with inflammatory cell infiltration, ballooned
hepatocytes, and pericellular, “chicken wire,” fibrosis (1–4).
NASH-induced fibrosis may further progress to cirrhosis,
and up to 13% of NASH patients with cirrhosis eventually
develop hepatocellular carcinoma (HCC) (1–5). Currently,
NASH-mediated cirrhosis is the second leading cause of liver
transplantation, and it is predicted that this disease will be the
leading cause of liver transplantation within the next 10 years
(5). To date, lifestyle intervention, including weight loss and
exercise, is the primary treatment for NAFLD, and there is no
effective preventive or therapeutic drugs for NAFLD. Since there
is a chronic shortage of liver donors, an unmet need for new and
effective therapies for NAFLD is significant.
Not only in the human healthcare field, but also in veterinary
medicine field, liver disease is a significant health concern in
canines and felines (6). Hepatic lipidosis, which shares similar
histological morphologies with human NAFLD, developed in
the elderly, overweight cats that lost weight after not eating for
days to weeks (6). This condition often leads to unfavorable
clinical outcomes. Similar to that of human NAFLD, there is
also a significant unmet need for effective therapies for fatty liver
disease in animals.
Hepatocyte growth factor (HGF) is a multifunctional
pleiotropic cytokine. HGF is initially produced as a biologically
inactive, single-chain precursor form (7). After proteolytic
cleavage, pro-HGF converts to the active form consisting
of heterodimeric 69 kDa α-chain and 34 kDa β-chain
(7). The active form of HGF promotes tissue regeneration,
protection, wound healing, angiogenesis, tumorigenesis, and
anti-inflammatory, anti-apoptotic, and anti-fibrotic responses
Abbreviations: ALT, alanine aminotransferase; CDAA, choline-deficient amino
acid defined; CSAA, choline-supplemented amino acid defined diet; HCC,
hepatocellular carcinoma; H&E, hematoxylin and eosin; HCC, hepatocellular
carcinoma; HGF, hepatocyte growth factor; MMP, matrix metalloprotease;
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis;
PCNA, proliferating cellular nuclear antigen; PCR, polymerase chain reaction;
SMA, smooth muscle actin.
in a wide variety of organs, through binding to its receptor
MET. In the liver, HGF plays a crucial role in liver
regeneration after hepatectomy or massive liver damage,
protection against hepatocyte apoptosis and necrosis, and
suppression of liver fibrosis progression (7). Previous studies
reported that administration of recombinant HGF mitigated
alcohol-induced liver damage, ischemia-reperfusion liver injury,
endotoxin-induced fulminant hepatitis, and liver fibrosis (8–
12). The studies using transgenic mice overexpressing Hgf and
hepatocyte-specific c-met knockout mice, indicate the protective
role of the HGF-MET pathway in the development of NAFLD
(13, 14). Although there is a report with the application using
HGF gene therapy on a rat model of NAFLD-fibrosis (15), to the
best of our knowledge, the therapeutic effect of recombinant HGF
protein on the development of NASH has not been reported.
The high-fat diet-induced fatty liver model does not develop
liver injury, inflammation, and fibrosis in a short period
of feeding. The feeding of methionine-choline-deficient diet,
commonly used for NASH preclinical studies, significantly
reduces their body weight. These models do not well-recapitulate
the pathophysiology of human NAFLD. Notably, rodents fed a
choline-deficient amino acid-defined (CDAA) diet for 3 weeks
develop hepatic steatosis, inflammation, and mild liver fibrosis
without reducing body weight (16, 17). Therefore, we decided to
use CDAA diet feeding to develop a mouse model of NASH in
this study.
The primary purpose of this study is to investigate
the therapeutic effect of recombinant HGF protein on the
progression of NASH. Since the amino acid sequence of feline
HGF shows 97.5, 93.3, and 93.2% homology with those of canine,
mouse, and human (18, 19), the second aim of this study is that
to examine whether feline-derived recombinant HGF can be used
for the treatment of animals with liver diseases using a mouse
model of NASH.
MATERIALS AND METHODS
Animal Experiments
Animal experiments were performed in accordance with
National Institutes of Health recommendations outlined in
the Guide for the Care and Use of Laboratory Animals. All
animal experiment protocols were approved by the University
of California San Diego Institutional Animal Care and Use
Committee. Male C57BL/6 mice were purchased from The
Jackson Laboratory (Bar Harbor, MA) and were maintained in a
12 h light/dark cycle. Mice at 8 weeks of age were subjected to
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feeding ad libitum either choline-supplemented L-amino acid-
defined diet (CSAA; catalog #518754; Dyets Inc, Bethlehem,
PA) or choline-deficient L-amino acid-defined diet (CDAA;
catalog #518753; Dyets Inc) for 3 weeks. Vehicle or 1 mg/kg of
recombinant feline HGF was intravenously injected daily during
the last 7 days.
Histologic Examination
Mouse liver tissues were fixed in 10% neutral buffered formalin
phosphate (Fisher Scientific, Pittsburgh, PA) and then embedded
into paraffin blocks. 5-µm thick sections were cut on a
microtome (Thermo Scientific, Waltham, MA). Tissues were
stained with hematoxylin and eosin for the evaluation of NAFLD
Activity Score (steatosis, lobular inflammation, hepatocyte
ballooning) and fibrosis as described (20). Immunochemistry
for proliferating cellular nuclear antigen (PCNA), F4/80 and
Sirius Red staining were performed as previously reported (21,
22). In brief, liver sections were incubated with monoclonal
antibody to PCNA (clone PC10; Biolegend, San Diego, CA) using
the MOM kit (Vector Laboratories, Burlingame, CA). Sections
were incubated with monoclonal antibody to F4/80 (clone BM8;
eBioscience, San Diego, CA) for immunohistochemical analysis
of F4/80 expression or incubated with a solution of saturated
picric acid containing 0.1% Fast Green FCF (Sigma-Aldrich, St
Louis, MO) and 0.1% Direct Red 80 (Sirius Red R3B; Sigma-
Aldrich, St Louis, MO) for Sirius Red staining. For Oil Red O
staining, mouse liver tissues were fixed in 4% neutral buffered
formalin phosphate and then embedded into OCT compound.
Frozen liver tissues were sliced into 5-µm sections and stained
with Oil Red O. PCNA or F4/80 or Oil Red O-positive area was
evaluated from randomly selected 10 fields of x200 magnification
per slide and quantified with NIH Image J software.
Serum Alanine Aminotransferase (ALT),
Triglyceride, and Total Cholesterol
Measurement
Blood was collected via cardiac puncture, centrifuged at 5,000
rpm for 15min, and the serum was frozen immediately. Serum
ALT levels were determined by Infinity ALT (GPT) liquid
stable reagent (Thermo Scientific, Middletown, VA) according to
manufacturer’s protocol. Serum triglyceride and total cholesterol
levels were determined by Triglycerides liquid reagent set (Pointe
Scientific, Inc., Canton, MI) and Cholesterol E CHOD-DAOS
method (Wako, Osaka, Japan), respectively.
Quantitative Real-Time Polymerase Chain
Reaction (qPCR)
The total RNAs were extracted from snap-frozen mouse
liver tissues using NucleoSpin R© RNA kit (Macherey-Nagel,
Düren, Germany). Reverse-transcribed with High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA) and iTaqTM Universal SYBR R© Green Supermix
(Bio-rad, Hercules, CA) were used. The sequences of mouse
PCR primers are listed in Table 1. Quantitative real-time PCR
was performed using CFX96 real-time PCR system (Bio-rad,
Hercules, CA).
TABLE 1 | Primer sequence used for qRT-PCR.
Gene Forward Reverse
18S AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA
Fasn GTTGGCCCAGAACTCCTGTA GTCGTCTGCCTCCAGAGC
Dgat1 TCACCACACACCAATTCAGG GACGGCTACTGGGATCTGA
Cxcl1 TGCACCCAAACCGAAGTC GTCAGAAGCCAGCGTTCACC
Ccl2 ATTGGGATCATCTTGCTGGT CCTGCTGTTCACAGTTGCC
Ccl5 CCACTTCTTCTCTGGGTTGG GTGCCCACGTCAAGGAGTAT
Col1a1 TAGGCCATTGTGTATGCAGC ACATGTTCAGCTTTGTGGACC
Acta2 GTTCAGTGGTGCCTCTGTCA ACTGGGACGACATGGAAAAG
Timp1 AGGTGGTCTCGTTGATTTCT GTAAGGCCTGTAGCTGTGCC
Tgfb1 GTGGAAATCAACGGGATCAG ACTTCCAACCCAGGTCCTTC
Serpine1 TTCAGCCCTTGCTTGCCTC ACACTTTTACTCCGAAGTCGGT
Statistical Analysis
Differences between the two groups were compared using the
Mann Whitney U-test or two-tailed unpaired student t-test.
Differences between multiple groups were compared using one-
way ANOVA. Statistical significance was assessed by using
GraphPad Prism 5.01 software (GraphPad Software, Inc, La Jolla,
Ca). P < 0.05 were considered significant.
RESULTS
The Therapeutic Effect of Recombinant
HGF Protein in a Mouse Model of NASH
Induced by CDAA Diet Feeding
To investigate the therapeutic effect of recombinant HGF
protein on a CDAA diet-induced mouse NASH model, wild-
type C57BL/6 mice were treated with vehicle or 1 mg/kg
of recombinant feline HGF protein intravenously in the last
7 days of a total of 3 weeks of CDAA diet feeding. Based
on NAFLD activity scoring system, we assessed the effect of
recombinant HGF on CDAA diet-induced NASH. Three weeks
of CDAA diet feeding showed an evident accumulation of
lipid droplets in hepatocytes, inflammatory cell infiltration,
ballooned hepatocytes, and mild fibrosis in the vehicle-treated
mice compared to CSAA diet feeding. The recombinant
HGF treatment significantly suppressed the development of
inflammation, hepatocyte ballooning, and fibrosis induced by
CDAA diet feeding (Figures 1A,B). Our results indicate that
recombinant HGF treatment administered on the last 7 days of
CDAA diet, improved NAFLD activity score.
Recombinant HGF Administration Inhibits
CDAA Diet-Induced Liver Damage and
Increases Hepatocyte Proliferation
To examine the protective effect of recombinant HGF on NASH-
mediated hepatocyte damage, serum ALT levels were measured.
Three weeks of CDAA diet feeding dramatically elevated serum
ALT levels in vehicle-treated mice, whereas increased serum ALT
levels by CDAA diet feeding were significantly reduced by the
administration of recombinant HGF protein (Figure 2). This
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FIGURE 1 | Recombinant HGF administration inhibited CDAA diet-induced
NASH. Male C57BL/6 mice were fed a CSAA or CDAA diet for 3 weeks. In the
last 7 days, vehicle (Veh) or 1 mg/kg of recombinant feline HGF were given
intravenously daily (CSAA-Veh, n = 8; CSAA-HGF, n = 10; CDAA-Veh, n = 13;
CDAA-HGF, n = 11). (A) H&E staining. Original magnification, x200. (B)
NAFLD activity score. Hepatic steatosis, inflammation, hepatocyte ballooning,
and fibrosis were evaluated through H&E stains. Data are presented as mean
± S.D. (**P < 0.01, significantly different from CSAA-Veh; #P < 0.05, ##P <
0.01, significantly different from CDAA-Veh).
FIGURE 2 | CDAA diet-mediated liver damage was suppressed by
recombinant HGF treatment. Serum ALT level. Data are presented as mean ±
SEM. (**P < 0.01, significantly different from CSAA-Veh; ##P < 0.01,
significantly different from CDAA-Veh).
result indicates that the 7 days of recombinant HGF treatment
suppressed hepatocyte damage induced by the 3 weeks of CDAA
diet feeding in mice.
Since HGF is a potent mitogen, we next evaluated the effect
of exogenous HGF on hepatocyte proliferation. The increases
in PCNA labeling were observed in both HGF-treated CSAA
diet-fed and CDAA diet-fed mice (Figures 3A,B).
Recombinant HGF Protein Has
Anti-lipogenesis Effect in CDAA
Diet-Induced Hepatic Steatosis
In addition to the assessment of steatosis by NAFLD activity
scoring system, using hematoxylin and eosin staining, hepatic
steatosis was examined by oil red O staining. A previous report
showed that H&E steatosis assessment poorly correlated with
triglyceride concentration in the tissue, whereas Oil Red O
staining showed much higher sensitivity and specificity for
steatosis (23).
Three weeks of CDAA diet feeding induced accumulation of
large lipid droplets in hepatocytes in vehicle-treated mice but,
CSAA diet feeding did not (Figures 4A,B). Serum triglyceride
and total cholesterol levels were unchanged (Table 2). Seven
days of daily administration of recombinant HGF protein
significantly suppressed accumulation of lipid droplets in
hepatocytes (Figures 4A,B). The study then assessed lipogenesis-
related gene expression. Quantitative real-time PCR analysis
shows that increased Fasn and Dgat1 genes by CDAA diet
feeding were significantly suppressed in mice treated with
recombinant HGF protein (Figure 4C). These results suggest
that HGF treatment inhibits hepatic lipid accumulation through
inhibiting expression of lipogenesis-related genes, such as Fasn
and Dgat1.
CDAA Diet-Induced Hepatic Inflammation
Is Suppressed by Recombinant HGF
Treatment
Inflammatory cell infiltration is a prominent feature of NASH.
Among inflammatory cells, hepatic macrophages comprising
liver resident Kupffer cells, and bone marrow-derived monocytes
are the significant contributor to NASH development. Liver
macrophages were examined by immunohistochemical staining
for F4/80, a mouse macrophage marker. While basal amounts
of liver macrophages were seen in mice fed with CSAA diet,
the number of liver macrophages and the foci containing
macrophages were significantly augmented in mice fed with
3 weeks of CDAA diet. Interestingly, the recombinant HGF
treatment reduced the amounts of liver macrophages in mice
fed CDAA diet compared to vehicle treatment (Figures 5A,B).
Inflammatory cell infiltration is mainly regulated by the
small size (8–10 kDa) of inflammatory cytokines, called
chemokines. Increased hepatic levels of Cxcl1, Ccl2, and Ccl5
induced by CDAA diet feeding were significantly reduced
by the treatment of recombinant HGF (Figure 5C). Our
results suggest that recombinant HGF protein has anti-
inflammatory effects on NASH livers that inhibit macrophage
infiltration and production of chemokines which play a
role in the recruitment of inflammatory cells to injured
livers.
Fibrogenic Response Induced by CDAA
Diet Was Suppressed by Recombinant HGF
Treatment
While 3 weeks of CDAA diet feeding does not induce strong
fibrillar collagen deposition, very mild collagen expression was
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FIGURE 3 | Administration of recombinant HGF promoted hepatocyte proliferation. (A) Representative images of PCNA staining. Original magnification, x200. (B)
Quantification of PCNA staining. Data are presented as mean ± SEM.
FIGURE 4 | Recombinant HGF protein attenuated CDAA diet-induced lipogenesis. (A) Oil red O staining of lipid droplets. Original magnification, x200. (B)
Quantification of Oil Red O staining. (C) Hepatic mRNA expression of Fasn and Dgat1. Data are presented as mean ± SEM. (*P < 0.05, **P < 0.01, significantly
different from CSAA-Veh; #P < 0.05, significantly different from CDAA-Veh).
seen in liver parenchyma (Figure 6A), which was diminished
by recombinant HGF treatment. Notably, there was evidence
of upregulation of fibrogenic gene expression in mice with 3
weeks feeding of CDAA. In the vehicle group, CDAA diet feeding
significantly upregulated Col1a1, Acta2, Timp1, Tgfb1, and
Serpine1 expression in the liver (Figure 6B). On the contrary, in
the recombinant HGF treatment group, upregulation of hepatic
expression of fibrogenic genes Col1a1, Acta2, Timp1, Tgfb1, and
Serpine1 was significantly inhibited (Figure 6B). These results
suggest that recombinant HGF treatment can inhibit hepatic
stellate cell activation and liver fibrosis progression in NASH.
DISCUSSION
The present study investigated the therapeutic potential of
recombinant HGF protein in the development of NASH in mice.
Our data demonstrated that 7 days of intravenous administration
of recombinant feline HGF protein is sufficient to suppress the
progression of a mouse model of NASH induced by 3 weeks
of CDAA diet feeding. The HGF protein treatment significantly
suppressed major pathological features of NASH, including
the accumulation of lipid droplets in hepatocytes, lipogenesis
gene expression, hepatocyte ballooning, elevation of serum ALT
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TABLE 2 | The serum triglyceride and cholesterol profiles.
CSAA CDAA
Vehicle HGF Vehicle HGF
(n = 4) (n = 3) (n = 16) (n = 12)
Triglycerides (mg/dl) 60.3 ± 21.6 68.3 ± 26.8 58.1 ± 14.4 60.2 ± 14.9
Total cholesterol (mg/dl) 94.9 ± 10.0 141.2 ± 45.5 96.8 ± 32.2 95.8 ± 44.0
Data are presented as mean ± S.D.
FIGURE 5 | Recombinant HGF protein had anti-inflammatory effect in CDAA diet-induced hepatic steatosis. (A) Immunohistochemistry for F4/80. Original
magnification, x200. (B) Quantification of F4/80 staining. (C) Hepatic mRNA expression of Cxcl1, Ccl2, and Ccl5. Data are presented as mean ± SEM. (*P < 0.05,
significantly different from CSAA-Veh; #P < 0.05, significantly different from CDAA-Veh).
levels, inflammatory cell infiltration, chemokine expression, and
fibrogenic gene expression. Our study strongly suggests that
administration of recombinant HGF protein can be a therapeutic
option for NASH.
The physiological role of HGF and its receptor MET in
the liver is well-described. HGF is initially produced and
released as an inactive precursor form and is normally found
in extracellular space. The major producer of HGF in the liver
is hepatic stellate cell which is a precursor of myofibroblasts
in the liver and contributes to the production of extracellular
matrix, progressing to liver fibrosis. During massive liver damage
induced by trauma, infection, toxin exposure, and inflammation,
pro-HGF is proteolytically cleaved by HGF activator, urokinase-
type plasminogen activator, matriptase, and so on, and becomes
the biologically active form of HGF (7). The active form of
HGF binds to its receptor MET, encoded by proto-oncogene
c-met, and induces its biological actions, including hepatocyte
proliferation, anti-apoptosis, wound healing, and liver tissue
homeostasis. Serum HGF levels were elevated in patients
with NASH compared to control group (24), proposing a
compensatory mechanism responsible for hepatic regeneration.
Because of the ability of HGF to induce hepatocyte proliferation
and liver regeneration, HGF has been suggested to be a potential
therapeutic agent for liver cirrhosis (25).
Hepatocyte damage and liver fibrosis are the key pathological
features in NASH. Even though serumHGF levels were increased
in NASH patients, it is unclear whether the active form of HGF
was also increased in NASH patients. In addition, HGF receptor,
MET was underexpressed in human NAFLD livers compared to
control livers (26). Our data demonstrated that exogenous HGF
treatment suppressed CDAA diet-induced hepatocyte damage
and fibrogenic response. Previous studies also demonstrated the
protective role of the HGF-MET pathway in liver injury and
fibrosis. Exogenous administration of recombinant HGF protein
suppresses lipopolysaccharide-induced or Fas-mediated mouse
models of fulminant hepatitis (12, 27, 28). In Fas-mediated liver
injury model, HGF induces Mcl-1 expression and activation of
Akt pathway, resulting in inhibition of hepatocyte apoptosis
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FIGURE 6 | Recombinant HGF ameliorated CDAA diet-induced fibrogenic response. (A) Sirius Red staining. Original magnification, x100. (B) Hepatic mRNA
expression of Col1a1, Acta2, Timp1, Tgfb1, and Serpine1. Data are presented as mean ± SEM. (*P < 0.05, **P < 0.01, significantly different from CSAA-Veh; #P <
0.05, significantly different from CDAA-Veh).
(28). In addition, HGF stimulates hepatocyte proliferation
(Figure 3), which is favorable to the liver repair process. Since
one of the major functions of HGF is the induction of matrix
metalloproteases (MMPs), such as membrane type 1-MMP and
MMP9 to degrade the extracellular matrix, a number of reports
demonstrated the therapeutic effect of HGF in liver fibrosis
(10, 11, 25, 29). HGF is also known to have an anti-inflammatory
property. HGF treatment reduced expression of TNF-α, CCL2,
and IL-6 in mouse culture macrophages, in which induction
of anti-inflammatory heme oxygenase-1 and IL-10 are partly
involved (30, 31). These reports are consistent with our data
showing that recombinant HGF treatment inhibited NASH-
mediated macrophage infiltration and chemokine expression in
the liver.
The protective effect of HGF against lipids in hepatocytes
has previously been reported. Recombinant HGF treatment
reduced intracellular lipid content, likely by accelerating lipid
secretion in hepatocytes through activation of microsomal
triglyceride transfer protein and apolipoprotein B (32).
Moreover, recombinant HGF treatment inhibited cholesterol
overload-mediated hepatocyte lipotoxicity by suppressing
production of reactive oxygen species (33). An animal
study using hepatocyte-specific c-met-deleted mice showed
exacerbation of a mouse model of NASH induced bymethionine-
choline deficient diet (13). All of these reports suggest both
exogenous and endogenous HGF-MET system play a critical
role in the protection of NAFLD development. Blockade of
mineralocorticoid receptor signaling attenuates hepatic steatosis
and insulin resistance in a mouse model of obesity. Interestingly,
the underlying mechanism of attenuated hepatic steatosis by
blocking mineralocorticoid receptor is mediated through the
HGF-MET pathway (34). Our data demonstrated that exogenous
HGF treatment reduced hepatic steatosis along with reduction of
lipogenesis genes, but it appears that the protective mechanism
of HGF is not mediated through modulation of lipid degradation
pathway as our data did not show any changes in the expression
of β-oxidation-related genes (data not shown).
Obesity and fatty liver disease have been often observed in cats
and dogs (35, 36). Like in humans, obesity is closely associated
with metabolic syndrome. High-fat diet feeding altered the
composition of fatty acid in liver tissue and serum (37). The
stearic acid-rich high fat diet promoted hepatic lipogenesis in
the feline liver (37). Feline hepatic lipidosis, also known as feline
fatty liver syndrome, is the most diagnosed liver disease in cats
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(38). This disease is life-threatening without treatment, but the
prognosis would be favored in cases of intensive treatment and
adequate therapy. The causes and pathogenic mechanisms are
scarcely known. Since our data clearly showed that exogenous
HGF treatment efficiently reduced the fat content in the liver
and inhibited CDAA diet-induced lipogenesis in mice, further
evaluation in large animals may be needed to determine the
efficacy and safety of HGF in fatty liver disease.
The MET overexpression and activation play a crucial role
in cancer cell proliferation, migration, invasion, and metastasis.
This signaling also contributes to drug resistance in tumor
microenvironment (39). In HCC, MET is overexpressed (40), but
some reports showed HGF is underexpressed (41–45). The effect
of HGF on hepatocarcinogenesis is controversial. HGF treatment
suppressed HCC cell growth in vitro in some reports (46, 47).
Exogenous HGF administration or HGF transgenic mousemodel
showed both pro- and anti-tumorigenic effects of HGF (48–56).
Nakanishi et al. tested the long-term effect of exogenous HGF
to the NASH mouse model on the occurrence of HCC (56).
According to their results, treatment with recombinant human
HGF did not increase the overall frequency of HCC. We suggest
that NAFLD patients or animals with cancer or individuals
with the potential to have cancer are not appropriate for HGF
treatment.
Besides the beneficial role of HGF in the liver, HGF is also
involved in tissue regeneration, protection, and homeostasis in
the kidney and neurons (57). Moreover, HGF is a potent inducer
of angiogenesis and has a protective role in the development
of cardiovascular diseases through modulation of atherosclerosis
(58). Given that the leading cause of death by NASH is
cardiovascular diseases (59), targeting of the HGF-MET pathway
should have beneficial effects on both liver and heart. Therefore,
it is worth considering HGF therapy for NAFLD, but the careful
selection of patients or animals may have to be considered due to
the capacity of HGF to promote cancer progression.
In summary, the present study demonstrated that exogenous
administration of recombinant feline HGF protein has potential
to mitigate the development of NASH. Although there is a
concern about the role of HGF played in cancer progression,
it should be considered for those individuals with low risk of
developing HCC (e.g., early stage of NASH fibrosis without
cirrhosis). Given that HGF can suppress the risk of cardiovascular
disease which is the leading cause of death in NASH patients,
exogenous HGF administration may be a favorable option for the
treatment of NAFLD.
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